ETHOS
VETERINARY HEALTH

# Seeking New Participants for our Carcinoma Study!

This study seeks to evaluate a novel immunotherapy when used in dogs with transitional cell or urothelial carcinoma. The therapy specifically targets an important molecule primarily expressed on immune cells, which usually turns off the immune cells and prevents overactive immune responses. However, it also turns off anti-cancer immune responses and prevents the immune system controlling and killing cancer cells. Immunotherapies that are able to inhibit this molecule on immune cells that recognize cancer cells could make it possible for the immune system to recognize and attack the underlying cancer more effectively.

## YOUR DOG MAY BE ELIGIBLE IF:

- Weigh ≥5kg and ≤35kg
- Histologically confirmed transitional cell or urothelial carcinoma, with or without documented lymph node involvement (newly diagnosed dogs and recurrent/relapsed disease)
- Measurable primary intravesicular tumor amenable for cystoscopic biopsy
- No significant comorbidities
- Expected survival time of at least 8 weeks
- History of daily drug administration for an unregulated chronic disease
- Prior experimental therapy, antibody therapies, immunomodulatory therapies within six weeks of study, or chemo/radiation therapy within two weeks of study
    - Dogs receiving standard of care NSAID for UC for at least 2 weeks prior to study enrollment will be allowed to continue SOC while on study

## CLIENT INCENTIVE:

Fully funded. All treatments and procedures will occur with no cost to the owner.

## INTERESTED?

If there are any questions or concerns regarding this study, feel free to reach us here:


**Dr. Megan Brown**

megan.brown3@nva.com

216-201-9840

ETHOS
VETERINARY HEALTH

# Carcinoma Study Schedule:

| Visit | 1 (Day -14 to -7) | 2 (Day 0) | 3 (Day 14) | 4 (Day 28) | 5 (Day 42) | 6 (Day 56) | 7, 8, 9, 10 (Every 8 wks) |
|---|---|---|---|---|---|---|---|
| Physical Exam | x | x | x | x | x | x | x |
| Blood Samples | x | x | x | x | x | x | x |
| Urine Samples | x | | x | x | x | x | x |
| Chest X-rays | x | | | | | x | x |
| Abdominal Ultrasound | x | | | x | | x | x |
| Cytoscopy & Tumor Biopsy | x | | | | | x | |
| Quality of Life Survey | x | | | x | | x | x |
| Therapy Administration | | x | x | x | x | x | |
| End Study | | | | | | | x (at visit 10) |

## INTERESTED?

If there are any questions or concerns regarding this study, feel free to reach us here:


**Dr. Megan Brown**

megan.brown3@nva.com

216-201-9840

ETHOS
VETERINARY HEALTH

# Seeking New Participants for our Carcinoma Study!

## Overview:

This study seeks to evaluate a novel immunotherapy when used in dogs with transitional cell or urothelial carcinoma. The therapy specifically targets an important molecule primarily expressed on immune cells, which usually turns off the immune cells and prevents overactive immune responses. However, it also turns off anti-cancer immune responses and prevents the immune system controlling and killing cancer cells. Immunotherapies that are able to inhibit this molecule on immune cells that recognize cancer cells could make it possible for the immune system to recognize and attack the underlying cancer more effectively.

## Eligibility:

- Weigh ≥5kg and ≤35kg
- Histologically confirmed transitional cell or urothelial carcinoma, with or without documented lymph node involvement (newly diagnosed dogs and recurrent/relapsed disease)
- Measurable primary intravesicular tumor amenable for cystoscopic biopsy
- No significant comorbidities
- Expected survival time of at least 8 weeks
- History of daily drug administration for an unregulated chronic disease
- Prior experimental therapy, antibody therapies, immunomodulatory therapies within six weeks of study, or chemo/radiation therapy within two weeks of study
  - Dogs receiving standard of care NSAID for UC for at least 2 weeks prior to study enrollment will be allowed to continue SOC while on study

## STUDY SCHEDULE:

| Visit | 1 (Day -14 to -7) | 2 (Day 0) | 3 (Day 14) | 4 (Day 28) | 5 (Day 42) | 6 (Day 56) | 7, 8, 9, 10 (Every 8 wks) |
|---|---|---|---|---|---|---|---|
| Physical Exam | x | x | x | x | x | x | x |
| Blood Samples | x | x | x | x | x | x | x |
| Urine Samples | x | | x | x | x | x | x |
| Chest X-rays | x | | | | | x | x |
| Abdominal Ultrasound | x | | | x | | x | x |
| Cytoscopy & Tumor Biopsy | x | | | | | x | |
| Quality of Life Survey | x | | | x | | x | x |
| Therapy Administration | | x | x | x | x | x | |
| End Study | | | | | | | x (at visit 10) |

## CLIENT INCENTIVE:

Fully funded. All treatments and procedures will occur with no cost to the owner.

## INTERESTED?

If there are any questions or concerns regarding this study, feel free to reach us here:


**Dr. Megan Brown**

megan.brown3@nva.com

216-201-9840